Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor

被引:49
作者
Robin, Marie
Porcher, Raphaeel
Araujo, Renato De Castro
De Latour, Regis Peffault
Devergie, Agnes
Rocha, Vanderson
Largbero, Jerome
Ades, Lionel
Ribaud, Patricia
Mary, Jean-Yves
Socie, Gerard
机构
[1] Greffe Hop St Louis, Serv Hematol, AP HP, F-75010 Paris, France
[2] Hop St Louis, Dept Biostat & Med Informat, Paris, France
[3] Hop St Louis, Unite Therapie Cellulaire, Paris, France
关键词
late infection; Bone marrow transplantation;
D O I
10.1016/j.bbmt.2007.07.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
After allogencic hematopoietic stem cell transplantation (HSCT), early infections represent a major cause of morbidity and mortality but little information has been previously reported on late infections. Late infection incidence and risk factors were retrospectively determined in 196 long-term survivors after HLA matched related HSCT. Patients transplanted for aplastic anemia, chronic myelogenous leukemia (CML), and acute myclogenous leukemia (AML) were included. Median follow-up was 8 years. Thirty patients died beyond the first year, causes of death were relapse (n = 10) and infections (n = 19, associated with graft-versus-host disease [GVHD] in 16 patients). Late severe bacterial (LSB) and fungal infections occurred in 30 and 8 patients, yielding to an 8-year cumulative incidence of 15 (95%Cl: 10-20) and 4% (95%Cl: 1-6), respectively. The majority of viral infections were hepatitis C (HCV) and VZV (8-year cumulative incidence: 10 (95%Cl: 5-14) and 27% (95%Cl: 20-34), respectively. Three risk factors for LSB have been identified in multiple Cox analysis: CNIV status (positive recipient and negative donor) (hazard ratio [HR]: 2.5, 95%Cl: 1.1-5.9, P =.033), irradiation-based conditioning regimen (HR: 3.1, 95%Cl: 1.2-7.8, P =.016), and extensive chronic GVHD (cGVHD; HR: 2.9, 95%Cl: 1.3-6.9, P =.013). Extensive cGVHD was the only risk factor for non-HCV viral infections in patients transplanted for AML or CML (HR: 2.7,95%Cl: 1.4-5.1, P =.002). After HSCT, patients remain at high risk of infections even late after transplantation, in particular, with the above risk factors, and required a prolonged follow-up. (c) 2007 American Society for Blood and AlIarrow Transplantation
引用
收藏
页码:1304 / 1312
页数:9
相关论文
共 38 条
[1]   Long-term outcome after bone marrow transplantation for severe aplastic anemia [J].
Ades, L ;
Mary, JY ;
Robin, M ;
Ferry, C ;
Porcher, R ;
Esperou, H ;
Ribaud, P ;
Devergie, A ;
Traineau, R ;
Gluckman, E ;
Socié, G .
BLOOD, 2004, 103 (07) :2490-2497
[2]  
ATKINSON K, 1982, BLOOD, V60, P714
[3]   Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study [J].
Boeckh, M ;
Kim, HW ;
Flowers, MED ;
Meyers, JD ;
Bowden, RA .
BLOOD, 2006, 107 (05) :1800-1805
[4]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[5]   The international sepsis forum consensus conference on definitions of infection in the intensive care unit [J].
Calandra, T ;
Cohen, J .
CRITICAL CARE MEDICINE, 2005, 33 (07) :1538-1548
[6]   Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation [J].
Clave, E ;
Rocha, V ;
Talvensaari, K ;
Busson, M ;
Douay, C ;
Appert, ML ;
Rabian, C ;
Carmagnat, M ;
Garnier, F ;
Filion, A ;
Socié, G ;
Gluckman, E ;
Charron, D ;
Toubert, A .
BLOOD, 2005, 105 (06) :2608-2613
[7]   Long-term outcome of hepatitis C infection after bone marrow transplantation [J].
de Latour, RP ;
Lévy, V ;
Asselah, T ;
Marcellin, P ;
Scieux, C ;
Adès, L ;
Traineau, R ;
Devergie, A ;
Ribaud, P ;
Espérou, H ;
Gluckman, E ;
Valla, D ;
Socié, G .
BLOOD, 2004, 103 (05) :1618-1624
[8]  
DEKKER A, 2004, CLIN BONE MARROW BLO, V73, P1158
[9]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[10]  
Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2